Fda approves Benlysta intravenous infusions for children with systemic lupus erythematosus
-
Last Update: 2021-02-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
systemic lupus (SLE), commonly referred to simply as lupus, is a serious chronic disease that causes inflammation and damage to various body tissues and organs.recently, the FDA approved Benlysta intravenous infusion (IV) for children under 5 years of age with systemic lupus erythematosus (SLE).clinical trial looked at the efficacy of belimumab, which evaluated the efficacy, safety and pharmacodynamics of 93 active SLE children aged 5-17 years with standard therapy and placebo plus standard therapy.children receiving belimumab IV plus standard treatment had a higher proportion of the combined primary endpoint SLE Response Index (SRI-4) than the placebo plus standard treatment group. Children receiving belimumab IV plus standard treatment have a lower risk of severe seizures and a longer duration until a severe seizure occurs (160 days VS 82 days). The drug's safety and pharmacodynamic characteristics in child patients are consistent with among adult SLE patients., belimumab includes a warning of death, severe infection, allergies and depression, according to the SLE Adult Clinical Study. The drug should not be used with live vaccines. The manufacturer must provide medication guidelines to inform the patient of the risks associated with belimumab.common side effects include nausea, diarrhea and fever. Patients also usually experience infusion reactions, so medical personnel are advised to pre-treat patients with antihistamines. (Drug Information Network)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
